C1orf218 Inhibitors
C1orf218 Inhibitors are characterized by their ability to interfere with various intracellular signaling cascades and processes that are putatively associated with the functional activity of C1orf218. The phosphoinositide 3-kinase (PI3K) inhibitor LY 294002 and the mTOR inhibitor Rapamycin are both capable of disrupting downstream AKT and mTOR signaling respectively, which may be crucial for the regulation of C1orf218, possibly affecting its synthesis or degradation. Inhibition by these compounds can lead to a reduction in the functional activity of C1orf218 by curtailing the pathway's influence on protein synthesisand stability. Similarly, MEK inhibitors like PD 98059 and U0126 target the ERK/MAPK pathway, a classic route for regulating various proteins, potentially including C1orf218. Inhibition of this pathway could prevent the activation or modification of C1orf218, resulting in a diminished functional state. The p38 MAPK inhibitor SB 203580 and the JNK inhibitor SP600125 further exemplify this approach by curtailing additional MAPK-related pathways that might intersect with C1orf218's regulatory mechanisms.
Compounds such as Bortezomib challenge C1orf218's activity by altering the proteasomal degradation pathway, which could lead to an accumulation of non-functional C1orf218 or its regulators. Cyclopamine and DAPT, which inhibit the Hedgehog and Notch signaling pathways respectively, could also decrease C1orf218's activity if it is influenced by these pathways. The EGFR inhibitor AZD5363 might suppress EGFR-related pathways, thereby indirectly decreasing C1orf218's activity if it is involved in EGFR signaling. Furthermore, ZM-447439 and Y-27632 target cell cycle progression and cytoskeletal dynamics, processes that could be fundamental to the proper functioning of C1orf218. By hindering these specific pathways, the selected inhibitors could lead to an overall reduction in the functional activity of C1orf218 within cellular environments, demonstrating the intricate interplay between various biochemical pathways and the modulation of protein function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that can lead to decreased AKT signaling. Since AKT can regulate a multitude of cellular processes, including protein synthesis and degradation, inhibition by LY 294002 could reduce the functional activity of C1orf218 if it is regulated by PI3K/AKT pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that interrupts the mTOR signaling pathway, which is a central regulator of cell growth and proliferation. Inhibition of mTOR could reduce protein synthesis, potentially diminishing C1orf218 levels if its expression is under control of mTOR activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A selective inhibitor of MEK1/2, which in turn inhibits the ERK/MAPK pathway. If C1orf218 is involved in this pathway, PD 98059 could reduce its activity by preventing its phosphorylation or the phosphorylation of associated regulatory proteins. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that could indirectly diminish C1orf218 activity by inhibiting p38 MAPK-mediated signaling pathways, assuming C1orf218 is involved in or regulated by these pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, which is part of the MAPK signaling pathways. If C1orf218 function is modulated by JNK activity, SP600125 could reduce its activity by diminishing JNK signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins. If C1orf218 is regulated via ubiquitination, bortezomib could potentially increase the levels of C1orf218, but it may also inhibit its function if C1orf218 requires regular turnover for its activity. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
An inhibitor of the Hedgehog (Hh) signaling pathway. If C1orf218 is a downstream effector of Hh signaling, its functional activity could be diminished by cyclopamine. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
A γ-secretase inhibitor that can prevent the cleavage of Notch receptors, thus inhibiting the Notch signaling pathway. If C1orf218 is part of the Notch pathway, DAPT could lead to decreased functional activity of C1orf218. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
An EGFR inhibitor that could reduce the activity of EGFR-mediated signaling pathways. If C1orf218 is an EGFR pathway component, its function could be inhibited by AZD5363. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
An Aurora kinase inhibitor that could disrupt cell cycle progression. If C1orf218 function is related to cell cycle regulation, ZM-447439 could indirectly diminish its activity. | ||||||